FMRI-neurofeedback in Depression
ConditionDepression, Unipolar
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMaastricht University Medical Center
About this trial
Previous studies with fMRI-neurofeedback in depression have demonstrated a good safety profile and considerable symptom reduction. The goal of this clinical trial is to compare fMRI-neurofeedback plus standard care with standard care in patients with depression.
Participants will either receive standard care, or standard care plus a fMRI neurofeedback training, consisting of 5 neurofeedback training sessions. Symptom severity will be assessed before, immediately after and 6 months after the intervention.
Eligibility criteria
Qualifiers
Diagnosis of a depressive disorder (ICD-10: F32 or F33)
Has been on stable antidepressant medication (single or combination treatment) for at least 4 weeks
Current depression (QIDS >= 17)
If required to meet recruitment targets the minimum entry score will be reduced QIDS >= 13 (i.e. still corresponding to a moderate level of depression)
Disqualifiers
Exclusion criteria for MRI (e.g. cardiac pacemaker, certain metallic implants)
History of psychotic disorder bipolar disorder, or psychotic depression
Current use of illegal drugs (any in the last four weeks)
Current excessive alcohol consumption that interferes with daily functioning
Trial design
Treatments tested in this trial
- fMRI-based neurofeedback
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov